Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report

Radium-223 is used for treating castration-resistant prostate cancer with bone metastases. Here, we report the case of a 76-year-old man diagnosed with castration-resistant prostate cancer with bone metastases who was started on radium-223. Although the patient ultimately died from causes unrelated...

Descripción completa

Detalles Bibliográficos
Autores principales: Dobashi, Masato, Kouguchi, Dai, Kanetsuna, Yukiko, Ishii, Junichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218028/
https://www.ncbi.nlm.nih.gov/pubmed/32420038
http://dx.doi.org/10.1016/j.eucr.2020.101230
_version_ 1783532710749274112
author Dobashi, Masato
Kouguchi, Dai
Kanetsuna, Yukiko
Ishii, Junichiro
author_facet Dobashi, Masato
Kouguchi, Dai
Kanetsuna, Yukiko
Ishii, Junichiro
author_sort Dobashi, Masato
collection PubMed
description Radium-223 is used for treating castration-resistant prostate cancer with bone metastases. Here, we report the case of a 76-year-old man diagnosed with castration-resistant prostate cancer with bone metastases who was started on radium-223. Although the patient ultimately died from causes unrelated to the treatment before starting the third treatment course, we observed that radium-223 was more effective in areas closer to the bone cortex than in deeper tumor regions. Through histopathological analysis, we provide important mechanistic insights on the therapeutic effect of radium-223 in human prostate cancer bone metastases.
format Online
Article
Text
id pubmed-7218028
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-72180282020-05-15 Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report Dobashi, Masato Kouguchi, Dai Kanetsuna, Yukiko Ishii, Junichiro Urol Case Rep Oncology Radium-223 is used for treating castration-resistant prostate cancer with bone metastases. Here, we report the case of a 76-year-old man diagnosed with castration-resistant prostate cancer with bone metastases who was started on radium-223. Although the patient ultimately died from causes unrelated to the treatment before starting the third treatment course, we observed that radium-223 was more effective in areas closer to the bone cortex than in deeper tumor regions. Through histopathological analysis, we provide important mechanistic insights on the therapeutic effect of radium-223 in human prostate cancer bone metastases. Elsevier 2020-05-03 /pmc/articles/PMC7218028/ /pubmed/32420038 http://dx.doi.org/10.1016/j.eucr.2020.101230 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Oncology
Dobashi, Masato
Kouguchi, Dai
Kanetsuna, Yukiko
Ishii, Junichiro
Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report
title Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report
title_full Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report
title_fullStr Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report
title_full_unstemmed Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report
title_short Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report
title_sort histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218028/
https://www.ncbi.nlm.nih.gov/pubmed/32420038
http://dx.doi.org/10.1016/j.eucr.2020.101230
work_keys_str_mv AT dobashimasato histopathologyofcastrationresistantprostatecancerconfirmschangesinbonemetastasisduringradium223treatmentacasereport
AT kouguchidai histopathologyofcastrationresistantprostatecancerconfirmschangesinbonemetastasisduringradium223treatmentacasereport
AT kanetsunayukiko histopathologyofcastrationresistantprostatecancerconfirmschangesinbonemetastasisduringradium223treatmentacasereport
AT ishiijunichiro histopathologyofcastrationresistantprostatecancerconfirmschangesinbonemetastasisduringradium223treatmentacasereport

Ejemplares similares